RxDoctor Payments Data

Hemal Parekh, MD

Critical Care Medicine · Miami, FLNPI 1033187588

Payments from drug & device makers

$454in general payments, 2019–2025

Across 24 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$227
  • AstraZeneca$60
  • GSK$54
  • Paratek Pharmaceuticals, Inc.$24
  • Baxter Healthcare$19
  • Sanofi$19
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$454100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$454 in reported general payments places this provider in the 50th percentile of 618 critical care medicine providers in Florida.

See all critical care medicine providers in Florida

Medicare billing

Part B allowed, 2024
$71,591
Medicare patients
215
Services billed
482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$53,987
Breztri AerosphereBudesonide/Glycopyr/Formoterol52$31,586
Breo ElliptaFluticasone/Vilanterol33$13,285
SymbicortBudesonide/Formoterol Fumarate49$12,799
Spiriva RespimatTiotropium Bromide17$10,231
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$6,466
Arnuity ElliptaFluticasone Furoate13$4,060
BreynaBudesonide/Formoterol Fumarate25$3,697
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$2,989
Omeprazole145$2,286
Wixela InhubFluticasone Propion/Salmeterol21$1,803
Albuterol Sulfate HfaAlbuterol Sulfate57$971
Fluticasone Propionate64$936
Azelastine Hcl15$633
Montelukast Sodium74$545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$54$77,797143 claims
AstraZenecaBreztri Aerosphere, Symbicort$60$44,385101 claims
Boehringer IngelheimSpiriva Respimat$227$10,23117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 618 critical care medicine providers in Florida.

Other critical care medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →